News BMS files Opdivo in post-surgery setting Opdivo performed better than BMS' Yervoy in clinical trial.
News AstraZeneca files Imfinzi for groundbreaking lung cancer use AZ also unveils promising results from early-stage lung cancer combination
Partner Content Partner Content ProQR Therapeutics: RNA Therapeutics for Patients with Cysti... RNA Therapeutics
News BMS scores an early victory in the new cancer biomarker batt... Bristol-Myers Squibb is hoping to drive forward its Opdivo cancer immunotherapy franchise by finding a better biomarker than PD-L1 - and has just produced encouraging results in a trial loo
News EU regulators back J&J's Zytiga in early prostate cancer use New use could give J&J drug edge over Pfizer's rival
News Cancer drug could cost NHS £4.7m per year of patient life, s... Roche's Erivedge is latest cancer drug to fall foul of NICE number-crunching.
Oncology ASCO 2026: AbbVie on ADCs, chemotherapy, and the future of o... For years, ADCs have been positioned as an important addition to the oncology toolkit. But, could they eventually replace chemotherapy altogether?
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
